Aton (ENXTPA: ALTAO)
Health Care · Biotechnology · FR
€0.02
-5.05% today · +141.5% 1Y
Aton (ENXTPA: ALTAO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $19.13M and employs 9 people.
Over the last twelve months the share price has gained 141.5%, trading between 0.01 and 0.03.
Tweenvest scores Aton across four factors: quality 37/100, value 34/100. Its strongest factor is quality.
ALTAO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $19.13M
- Revenue (TTM)
- $838.32K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.66
- 52-week high
- €0.03
- 52-week low
- €0.01
- Avg volume (3M)
- —
- Shares outstanding
- 828.12M
- Employees
- 9
- Next earnings
- —
About Aton
Based in France, Aton operates as a bioscience enterprise, with its headquarters located in Strasbourg. Established in 1998, the company's extensive operations encompass pharmaceutical research and development, the provision of preclinical and clinical services, and the creation of monoclonal antibodies. Additionally, Aton manufactures laboratory equipment, designs and produces various medical devices—including specialized surgical instruments powered by Stemcis technology—and supplies human tissues.
- ISIN
- FR0004153930
- Founded
- 1998
- Listed since
- Dec 21, 2007
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.75 | -0.02% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.55 | -0.16% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €898.00 | +2.14% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.87 | -0.60% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.